Literature DB >> 25895531

B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis.

Chelsea R Parker Harp1, Angela S Archambault1, Julia Sim2, Stephen T Ferris3, Robert J Mikesell1, Pandelakis A Koni4, Michiko Shimoda5, Christopher Linington6, John H Russell2, Gregory F Wu7.   

Abstract

B cells are increasingly regarded as integral to the pathogenesis of multiple sclerosis, in part as a result of the success of B cell-depletion therapy. Multiple B cell-dependent mechanisms contributing to inflammatory demyelination of the CNS have been explored using experimental autoimmune encephalomyelitis (EAE), a CD4 T cell-dependent animal model for multiple sclerosis. Although B cell Ag presentation was suggested to regulate CNS inflammation during EAE, direct evidence that B cells can independently support Ag-specific autoimmune responses by CD4 T cells in EAE is lacking. Using a newly developed murine model of in vivo conditional expression of MHC class II, we reported previously that encephalitogenic CD4 T cells are incapable of inducing EAE when B cells are the sole APC. In this study, we find that B cells cooperate with dendritic cells to enhance EAE severity resulting from myelin oligodendrocyte glycoprotein (MOG) immunization. Further, increasing the precursor frequency of MOG-specific B cells, but not the addition of soluble MOG-specific Ab, is sufficient to drive EAE in mice expressing MHCII by B cells alone. These data support a model in which expansion of Ag-specific B cells during CNS autoimmunity amplifies cognate interactions between B and CD4 T cells and have the capacity to independently drive neuroinflammation at later stages of disease.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25895531      PMCID: PMC4433779          DOI: 10.4049/jimmunol.1402236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  APCs present A beta(k)-derived peptides that are autoantigenic to type B T cells.

Authors:  Scott B Lovitch; James J Walters; Michael L Gross; Emil R Unanue
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

2.  Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis.

Authors:  Soomin Shin; Katharine A Walz; Angela S Archambault; Julia Sim; Bryan P Bollman; Jessica Koenigsknecht-Talboo; Anne H Cross; David M Holtzman; Gregory F Wu
Journal:  J Neuroimmunol       Date:  2014-03-29       Impact factor: 3.478

3.  Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

Authors:  Ludwig Kappos; Hans-Peter Hartung; Mark S Freedman; Alexey Boyko; Ernst Wilhelm Radü; Daniel D Mikol; Marc Lamarine; Yann Hyvert; Ulrich Freudensprung; Thomas Plitz; Johan van Beek
Journal:  Lancet Neurol       Date:  2014-03-06       Impact factor: 44.182

4.  De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis.

Authors:  Stephen Mark Tompkins; Josette Padilla; Mauro C Dal Canto; Jenny P-Y Ting; Luc Van Kaer; Stephen D Miller
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

5.  Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells.

Authors:  Nir Yogev; Friederike Frommer; Dominika Lukas; Kordula Kautz-Neu; Khalad Karram; Daniele Ielo; Esther von Stebut; Hans-Christian Probst; Maries van den Broek; Dieter Riethmacher; Tal Birnberg; Thomas Blank; Boris Reizis; Thomas Korn; Heinz Wiendl; Steffen Jung; Marco Prinz; Florian C Kurschus; Ari Waisman
Journal:  Immunity       Date:  2012-08-16       Impact factor: 31.745

6.  Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity.

Authors:  A J Slavin; J M Soos; O Stuve; J C Patarroyo; H L Weiner; A Fontana; E K Bikoff; S S Zamvil
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

7.  Cutting edge: Conditional MHC class II expression reveals a limited role for B cell antigen presentation in primary and secondary CD4 T cell responses.

Authors:  Angela S Archambault; Javier A Carrero; Lisa G Barnett; Nigel G McGee; Julia Sim; Jonathan O Wright; Tobias Raabe; Peiquin Chen; Hua Ding; Eric J Allenspach; Ioannis Dragatsis; Terri M Laufer; Gregory F Wu
Journal:  J Immunol       Date:  2013-06-14       Impact factor: 5.422

8.  Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice.

Authors:  Alfred R Oliver; Geoffrey M Lyon; Nancy H Ruddle
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

9.  Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein.

Authors:  Jeri-Anne Lyons; Michael J Ramsbottom; Anne H Cross
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

10.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.

Authors:  Ping Shen; Toralf Roch; Vicky Lampropoulou; Richard A O'Connor; Ulrik Stervbo; Ellen Hilgenberg; Stefanie Ries; Van Duc Dang; Yarúa Jaimes; Capucine Daridon; Rui Li; Luc Jouneau; Pierre Boudinot; Siska Wilantri; Imme Sakwa; Yusei Miyazaki; Melanie D Leech; Rhoanne C McPherson; Stefan Wirtz; Markus Neurath; Kai Hoehlig; Edgar Meinl; Andreas Grützkau; Joachim R Grün; Katharina Horn; Anja A Kühl; Thomas Dörner; Amit Bar-Or; Stefan H E Kaufmann; Stephen M Anderton; Simon Fillatreau
Journal:  Nature       Date:  2014-02-23       Impact factor: 49.962

View more
  42 in total

Review 1.  Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity.

Authors:  Ari Waisman; Lisa Johann
Journal:  J Mol Med (Berl)       Date:  2018-11-01       Impact factor: 4.599

2.  CNS-resident classical DCs play a critical role in CNS autoimmune disease.

Authors:  David A Giles; Patrick C Duncker; Nicole M Wilkinson; Jesse M Washnock-Schmid; Benjamin M Segal
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808

Review 3.  Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Authors:  Ai-Lan Nguyen; Melissa Gresle; Tessa Marshall; Helmut Butzkueven; Judith Field
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

4.  Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.

Authors:  Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

5.  B Cell-Mediated Antigen Presentation through MHC Class II Is Dispensable for Atherosclerosis Progression.

Authors:  Jesse W Williams; Andrew Elvington; Skyler Kessler; Mary Wohltmann; Gregory F Wu; Gwendalyn J Randolph
Journal:  Immunohorizons       Date:  2019-01-21

Review 6.  Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE.

Authors:  Luc Van Kaer; Joshua L Postoak; Chuan Wang; Guan Yang; Lan Wu
Journal:  Cell Mol Immunol       Date:  2019-03-15       Impact factor: 11.530

7.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

8.  Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease.

Authors:  Anne-Christine Flach; Tanja Litke; Judith Strauss; Michael Haberl; César Cordero Gómez; Markus Reindl; Albert Saiz; Hans-Jörg Fehling; Jürgen Wienands; Francesca Odoardi; Fred Lühder; Alexander Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-08       Impact factor: 11.205

9.  Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein.

Authors:  Jeri A Lyons; Melissa M Riter; Alaa M Almatrook; Michael J Ramsbottom; Anne H Cross
Journal:  J Neuroimmunol       Date:  2016-06-24       Impact factor: 3.478

Review 10.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.